Welcome to the Fangzhou Inc. Investor Relations Portal
We are China's leading online chronic disease management platform. We commenced our business with a focus on chronic disease management to address the needs of patients with chronic diseases, such as hypertension, cardiovascular and respiratory chronic diseases.
To address the needs of patients with chronic diseases for convenient and accessible medical care services, we provide comprehensive medical services and online retail pharmacy services through our Jianke Platform. Our comprehensive medical services include follow-up physician consultations and e-prescription services conducted by registered physicians and in-house medical professionals through our hospital-to-home (“H2H”) service platform. We also provide online retail pharmacy services, offering a wide range of pharmaceutical and healthcare products directly to our customers. Our comprehensive medical services and online retail pharmacy services are supported by our chronic disease management service center and robust pharmaceutical supply chain.
In addition, our platform's large and active user base allows us to effectively connect and engage with doctors and patients, providing them targeted medical knowledge and content. By leveraging these powerful network effects, our platform provides pharmaceutical companies with customized content and marketing solutions to better inform physicians and patients about chronic disease conditions and treatment options, as well as increase disease awareness among the public.
As of December 31, 2024, our chronic disease management service platform had approximately 49.2 million registered users. For the year ended December 31, 2024, our Jianke Platform recorded an average of approximately 10.1 million monthly active users. The number of registered physicians on our platform reached nearly 223 thousand as of December 31, 2024, and highlighting the exceptional caliber of medical professionals on our platform, approximately 59% of our registered physicians were affiliated with Class III hospitals, and approximately 39% held the title of associate chief physician or above.
Leveraging our chronic disease management platform, we are dedicated to providing tailored medical care and precision medicine for a growing population of chronic disease patients, with a view towards extending our services to a wider range of disease areas.
Company Honors:
2024
· Featured on the 2024 Guangdong "AI Catalyst" Enterprise Billboard at the Guangdong-Hong Kong-Macao Greater Bay Area Artificial Intelligence Industry Conference, recognizing the Company's role in advancing AI-driven healthcare solutions
· Received a "Most Valued Pharmaceutical & Healthcare Enterprise" award at the Zhitong Finance Capital Market Summit, affirming Fangzhou's industry leadership and strong performance
· Recognized as an "Outstanding Enterprise in Digital Intelligence" on the "Analysys Star 2024 Annual Award List", for substantial contributions to advancing the use of digital intelligence in the Internet healthcare sector and chronic disease management
2023
· Awarded "Southern Tribute-Annual Craftsmanship Enterprise" by Southern Daily
· Fangzhou subsidiary honored as a "2023 Guangdong Specialized and Innovative Small-Medium Enterprise", "Guangzhou Outstanding Software Enterprise" and "2023 Guangdong Influential Artificial Intelligence Enterprises List"
2022
· Awarded the 2022 Comprehensive Health Quality Manufacturing Leadership Award at the 3rd International Quality Festival/2022 Global Consumer Leadership Summit
· Elected to the List of Health Consumer Service Providers at the China International Consumer Products Expo - Global Healthcare Consumer Forum
· Received the 2022 Digital Transformation Catalyst Award at the 11th China Finance Summit